Accelerating the adoption of the fully automated immunoassay system “HISCL”
First written in FY2016. 7 of 11 entries say "Advanced", first in FY2022-Q1. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AdvancedAnnual report
「November 2025: We began sales in Japan of the immunoassay reagents HISCLTM Aldosterone Reagent and HISCLTM Renin Reagent, which support the early diagnosis of primary aldosteronism, one of the causes of hypertension.」
Launched aldosterone and renin reagents for the HISCL series in Japan, adding applications supporting early diagnosis of primary aldosteronism and treatment decisions. - FY2025-H1AdvancedAnnual report
「This product is an assay reagent for the fully automated blood coagulation analyzers CN™-6500/CN™-3500, which incorporate technology from the HISCL™ series, and delivers the high sensitivity and, additionally, high specificity required for serological testing of heparin-induced thrombocytopenia (HIT).」
Launched a HISCL™ series technology-based HIT assay reagent for the CN™-6500/CN™-3500, establishing the application of immunoassay technology in the blood coagulation field. - FY2024AdvancedAnnual report
「February 2024: We succeeded the manufacturing and marketing approvals for the HISCL TARC Reagent and HISCL ANP Reagent from Shionogi & Co.,Ltd. and began in-house manufacturing.」
For HISCL-related reagents, the company succeeded the manufacturing and marketing approvals for the TARC and ANP reagents and began in-house manufacturing. - FY2024-Q3AdvancedAnnual report
「December 2023: Domestic reimbursement coverage began for our assay reagent, HISCL M2BPGiTM-Qt Reagent, which can quantitatively assess the progression of liver fibrosis using only blood in the diagnosis and treatment of patients with chronic hepatitis and cirrhosis.」
For diagnostic applications using the HISCL series, the company disclosed a new clinical implementation: the start of domestic reimbursement coverage for the M2BPGi-Qt reagent. - FY2024-Q2AdvancedAnnual report
「August 2023: We began supplying a major testing laboratory in the United States with a reagent for measuring amyloid beta in blood as a reagent for laboratory-developed tests (LDTs). This LDT assists in assessing the accumulation of Aβ in the brain, which is considered a cause of Alzheimer's disease.」
Expanded the application of HISCL-based amyloid beta measurement from its launch in Japan to LDTs in the United States, and began supplying a major testing laboratory. - FY2024-Q1AdvancedAnnual report
「In the immunoassay field, we launched in Japan an assay reagent that uses a small blood sample to assess the accumulation of amyloid beta (Aβ) in the brain, which is a cause of Alzheimer's disease. Using the company's fully automated immunoassay analyzer HISCL™ series, based on the chemiluminescent enzyme immunoassay (CLEIA) method, the product measures the ratio of Aβ peptides in blood, specifically the 1-42 and 1-40 peptides, to assist in assessing the accumulation of Aβ in the brain.」
Launched a blood Aβ assay reagent in Japan for use with the HISCL™ series, establishing a new diagnostic application related to Alzheimer's disease. - FY2022-Q1AdvancedAnnual report
「We obtained approval for an additional indication for the Th2 chemokine TARC kit HISCL™ TARC Reagent, jointly developed by us and Shionogi & Co.,Ltd., to assist in assessing the risk of severe disease in patients testing positive for SARS-CoV-2.」
Approval was obtained for an additional indication of the HISCL-based TARC reagent to assist in assessing the risk of severe disease in SARS-CoV-2-positive patients. - FY2021RestatedAnnual report
「To help prevent the spread of COVID-19, we launched reagents for use with the fully automated immunoassay analyzers HISCL™-5000/HISCL™-800 that can detect coronavirus antigens causing COVID-19, as well as reagents to assist in assessing the risk of severe COVID-19 in patients.」
The company has reiterated the introduction of HISCL-based reagents for COVID-19 antigen testing and severe disease risk assessment as an achievement of its business activities. - FY2018RestatedAnnual report
「We aim to create new businesses, including ultra-high-sensitivity HISCL, a cervical cancer testing system, and glucose AUC, a postprandial hyperglycemia monitoring system.」
The company has reiterated its policy of creating new testing and monitoring businesses, including ultra-high-sensitivity HISCL. - FY2017RaisedAnnual report
「We aim to create new businesses, including ultra-high-sensitivity HISCL, a cervical cancer testing system, and glucose AUC, a postprandial hyperglycemia monitoring system.」
In addition to accelerating HISCL adoption, the company is expanding its scope to create businesses in multiple new testing fields, including ultra-high-sensitivity HISCL. - FY2016First statedAnnual report
「Accelerating adoption of the fully automated immunoassay analyzer HISCL by leveraging unique items and strengthening the service and support structure」
A plan to jointly strengthen the expansion of HISCL adoption and post-installation service and support.